Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what progress his Department has made on licencing the Harvoni form of ledipasvir-sofosbuvir for people who have been contaminated by blood products; and if he will make a statement.

Harvoni (ledipasvir-sofosbuvir) has been authorised by the European Commission and a Marketing Authorisation was issued on 17 November 2014 for the treatment of chronic hepatitis C in adults.

The National Institute for Health and Care Excellence is currently developing technology appraisal guidance for the National Health Service on the clinical and cost-effectiveness of Harvoni (ledipasvir-sofosbuvir) in the treatment of chronic hepatitis C and expects to publish its final guidance later this year.